Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Dermatology Excimer Laser Market Size & Share 2026-2035
Report ID: GMI13379
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Dermatology Excimer Laser Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Dermatology Excimer Laser Market Size
The dermatology excimer laser market was valued at USD 673 million in 2025, is expected to reach USD 740 million in 2026, is projected to grow at a 10% CAGR (2026-2035), and is forecast to reach USD 1.74 billion by 2035. The market covers 308 nm targeted ultraviolet B excimer systems sold in trolley-mounted, tabletop, and handheld configurations for lesion-directed dermatologic care.
Dermatology Excimer Laser Market Key Takeaways
Market Leader: STRATA Medical led with over 22% market share in 2025.
Leading Players: Top 5 players in this market include STRATA Medical, DEKA M.E.L.A., Alma Lasers, Sincoheren, Kernel Medical, which collectively held a market share of 61% in 2025.
The dermatology excimer laser market is expanding as clinicians and patients seek localized treatment pathways that can address inflammatory and pigmentary conditions while limiting systemic exposure. Demand is increasingly shaped by the ability of a single platform to support multiple indications, fit different practice footprints, and align with evolving reimbursement and procedural workflows.
GMI Analyst View
Our discussions with industry participants and GMI's proprietary market engagement indicate that the dermatology excimer laser market generated USD 505 million in revenue in 2022 - the base year of the approved historic reference period - establishing a growth trajectory characterized by consistent double-digit annual expansion well before the reimbursement-expansion dynamics and clinic-sector growth now driving the forecast outlook came fully into effect. This historic baseline reflects both the early penetration gains achieved in private clinic and hospital settings and the market's demonstrated capacity for sustained demand generation across economic cycles, a quality that GMI's forecast projections carry forward with confidence through 2035.
Dermatology Excimer Laser Market Trends, Growth Drivers & GMI Forecast Outlook
Demand is moving beyond a psoriasis-centered purchasing case toward a broader, multi-indication treatment model. Device adoption will depend on whether providers can translate rising clinical need, reimbursement access, and workflow flexibility into recurring procedure volumes across specialist and private-practice settings.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Vitiligo treatment demand is particularly supportive of targeted phototherapy because visible, localized lesions often require repeated site-specific intervention rather than generalized treatment. This clinical profile favors practices that can offer a procedure-led care option alongside topical therapies and systemic treatment pathways.
For psoriasis, excimer systems retain relevance where localized plaques, difficult-to-treat anatomical sites, or combination regimens warrant concentrated ultraviolet B delivery. Their role is therefore not limited to monotherapy; device utilization can remain durable when clinicians integrate phototherapy into individualized treatment sequencing.
The reimbursement revision broadens the commercial logic for multi-indication systems. Providers can evaluate excimer platforms against a wider procedural base, which may improve equipment utilization and reduce the dependence of purchasing decisions on a single reimbursable diagnosis.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Historical reimbursement restrictions have constrained the economic case for broad excimer deployment, especially in clinics that need predictable procedure volumes to support capital-equipment investment. Expanded coding eligibility can improve utilization economics, but provider uptake will still depend on payer implementation, documentation practices, and referral patterns.
Weak disease surveillance is a practical commercialization constraint, not merely an epidemiological limitation. Where national data and treatment pathways remain underdeveloped, providers may be slower to invest in specialized phototherapy capacity, leaving early demand concentrated in private practices and urban specialty centers.
Systemic biologics create a meaningful competitive boundary in psoriasis, particularly for patients requiring broad disease control or rapid clearance. Excimer platforms remain differentiated where localized treatment, combination care, or avoidance of systemic exposure is clinically appropriate, but manufacturers must position their systems around these use cases rather than assume substitution across all patient populations.
GMI Analyst View
We view the shift toward an indication-diverse demand base as a structural strengthening of the market. Vitiligo and alopecia areata can broaden the utilization case for installed systems, while combination protocols allow phototherapy to retain clinical relevance even as systemic treatment options become more sophisticated.
Dermatology Excimer Laser Market Segment Analysis
By Product Type
Trolley Mounted: Trolley-mounted systems are the leading product segment of the dermatology excimer laser market, generating USD 303 million in 2025 and forecast to account for 40.0% of global revenue by 2035. Their installed-base role in hospitals and high-throughput clinics supports continued demand, although long replacement cycles and capital-budget discipline can moderate purchasing momentum.
Tabletop: Tabletop systems held 38.0% of global revenue in 2025 and are projected to grow at a 10.0% CAGR (2026-2035). Their compact footprint suits specialist practices seeking a dedicated treatment platform without the space and workflow requirements associated with larger clinical installations.
Handheld: Handheld systems are forecast to reach USD 383 million by 2035 and grow at a 12.9% CAGR (2026-2035). Portability and lower acquisition thresholds can widen access among smaller dermatology practices, while supporting treatment models centered on localized lesions and flexible procedure delivery.
By Disease Indication
Psoriasis: The psoriasis segment generated USD 256 million in 2025 and is forecast to account for 35.0% of global revenue by 2035. Psoriasis remains an important procedural base for excimer providers, but its share of demand is shaped by the availability of biologics and the growing relevance of other phototherapy-responsive indications.
Vitiligo: Vitiligo represented 30.0% of global revenue in 2025 and is forecast to reach USD 575 million by 2035. The segment benefits from the clinical value of lesion-targeted therapy, particularly where patients seek treatment options that can be incorporated into longer-term dermatologic management plans.
Eczema / Atopic Dermatitis: Eczema and atopic dermatitis generated USD 94 million in 2025 and are projected to grow at a 10.0% CAGR (2026-2035). Broader reimbursement eligibility can strengthen the addressable treatment pool, while localized disease management may create a complementary role for excimer therapy alongside topical and systemic care.
Alopecia Areata: Alopecia areata is forecast to reach USD 157 million by 2035 and grow at an 11.3% CAGR (2026-2035). Evidence from a systematic review and meta-analysis indicates that laser and light therapy combined with topical agents can improve hair-regrowth outcomes, supporting interest in combination-oriented treatment protocols. [5]Lasers in Medical Science. "Laser and Light Therapy Combined with Topical Minoxidil for Alopecia Areata: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." link.springer.com
Allergic Rhinitis: Allergic rhinitis accounted for 5.0% of global revenue in 2025 and is forecast to grow at a 7.3% CAGR (2026-2035). Its comparatively narrower role reflects a more specialized treatment pathway, but it contributes to the broader multi-indication value proposition of excimer platforms.
By End Use
Dermatology & Cosmetic Clinics: Dermatology and cosmetic clinics generated USD 323 million in 2025 and are forecast to reach USD 871 million by 2035. These settings are positioned to benefit from localized treatment demand, flexible purchasing requirements, and the ability to integrate excimer procedures into recurring patient-care pathways.
Hospitals: Hospitals accounted for 35.1% of global revenue in 2025 and are projected to grow at an 8.9% CAGR (2026-2035). Their purchasing behavior is influenced by capital-allocation processes and multidisciplinary treatment capacity, which can support utilization but extend replacement and procurement cycles.
Plastic Surgery Centers: Plastic surgery centers are forecast to reach USD 192 million by 2035 and grow at an 11.1% CAGR (2026-2035). Growth reflects the increasing overlap between aesthetic-service infrastructure and specialty dermatologic care, particularly for patients seeking targeted management of visible skin conditions.
GMI Analyst View
: We believe product portability and indication breadth are becoming more important than traditional equipment scale in determining competitive advantage. Systems that can fit smaller practice settings while supporting repeatable, multi-indication procedures should be better positioned as care shifts toward specialized outpatient delivery.
Dermatology Excimer Laser Market Regional Analysis
North America Dermatology Excimer Laser Market Analysis
The dermatology excimer laser market in North America generated USD 282 million in 2025 and is forecast to reach USD 609 million by 2035. The region combines established specialty-care infrastructure with a reimbursement environment that can support adoption as covered indications expand.
U.S. The U.S. generated USD 262 million in 2025 and is forecast to account for approximately 90.0% of North American revenue by 2035. Its scale reflects the concentration of dermatology practices, procedure-oriented care models, and manufacturer commercial activity.
Canada Canada represented 7.1% of North American revenue in 2025 and is forecast to grow at an 11.8% CAGR (2026-2035). Demand is supported by specialist-led care, although provincial reimbursement structures and equipment procurement processes can influence the pace of expansion.
Europe Dermatology Excimer Laser Market Analysis
Europe accounted for 25.7% of global revenue in 2025 and is projected to grow at a 9.2% CAGR (2026-2035). Regional demand is shaped by established dermatology services, diverse reimbursement systems, and clinician interest in non-systemic options for localized disease management.
Germany Germany generated USD 35 million in 2025 and is forecast to account for 17.9% of European revenue by 2035. Its role is supported by a developed specialist-care environment and a large base of dermatology providers capable of incorporating procedure-based therapies.
UK The UK represented 18.5% of European revenue in 2025 and is forecast to grow at a 7.5% CAGR (2026-2035). Adoption is likely to remain influenced by public-sector treatment pathways, capital prioritization, and the availability of phototherapy services within specialist settings.
France France is forecast to reach USD 57 million by 2035 and grow at an 8.6% CAGR (2026-2035). Market development depends on the extent to which dermatology providers can position localized phototherapy within established clinical pathways for inflammatory and pigmentary conditions.
Italy Italy generated USD 18 million in 2025 and is forecast to reach USD 40 million by 2035. Private dermatology capacity and patient demand for targeted outpatient treatments support the market, while institutional procurement remains an important determinant of equipment placement.
Asia Pacific Dermatology Excimer Laser Market Analysis
Asia Pacific is forecast to reach USD 505 million by 2035 and grow at a 12.4% CAGR (2026-2035). The region's momentum reflects expanding private dermatology infrastructure, a large addressable patient base, and growing availability of locally manufactured systems.
China China generated USD 63 million in 2025 and is forecast to reach USD 237 million by 2035. Domestic manufacturing capabilities and broad expansion in private specialty care can strengthen equipment availability and improve the commercial reach of excimer therapy.
India India represented 15.3% of Asia Pacific revenue in 2025 and is forecast to grow at a 14.7% CAGR (2026-2035). Growth is supported by expanding urban dermatology networks and a care model in which private clinics can introduce targeted procedures without relying solely on large hospital installations.
Japan Japan is forecast to reach USD 50 million by 2035 and represented 12.7% of Asia Pacific revenue in 2025. STRATA Skin Sciences received Japanese regulatory approval for its XTRAC Momentum 1.0 device, supporting the availability of a dedicated excimer platform in the market. [6]STRATA Skin Sciences. "STRATA Skin Sciences Announces Approval of XTRAC Momentum™ 1.0 Device in Japan." investors.strataskinsciences.com
South Korea South Korea is forecast to account for 8.9% of Asia Pacific revenue by 2035 and grow at an 11.5% CAGR (2026-2035). Its advanced dermatology and aesthetic-treatment infrastructure can support adoption where providers see value in precise, outpatient-oriented treatment technologies.
Latin America Dermatology Excimer Laser Market Analysis
Latin America generated USD 34 million in 2025 and is forecast to account for 7.0% of global revenue by 2035. Growth is concentrated in private dermatology settings, where patients and clinicians can access specialized procedures despite uneven public reimbursement and institutional capacity.
Brazil Brazil generated USD 18 million in 2025 and is forecast to reach USD 67 million by 2035. Its scale reflects the country's substantial private dermatology and aesthetic-care base, which can provide an early channel for targeted phototherapy adoption.
Mexico Mexico is forecast to account for 25.4% of Latin American revenue by 2035 and grow at a 13.0% CAGR (2026-2035). Market expansion is linked to private specialty-care growth and the increasing availability of compact equipment formats suited to outpatient practices.
Middle East & Africa (MEA) Dermatology Excimer Laser Market Analysis
Middle East & Africa is forecast to reach USD 87 million by 2035 and accounted for 4.0% of global revenue in 2025. Demand remains concentrated in higher-income urban markets and private specialty facilities, where equipment access and procedural reimbursement are more favorable.
Saudi Arabia Saudi Arabia generated USD 8 million in 2025 and is forecast to account for 31.0% of Middle East & Africa revenue by 2035. Investment in specialist healthcare capacity and demand for advanced outpatient services provide a foundation for wider excimer-system placement.
UAE The UAE represented 22.2% of Middle East & Africa revenue in 2025 and is forecast to reach USD 19 million by 2035. Its private healthcare and medical-service ecosystem supports adoption of technologies that combine clinical dermatology with efficient patient-throughput models.
GMI Analyst View
: We see regional performance becoming increasingly differentiated by care-delivery infrastructure rather than disease prevalence alone. Mature reimbursement and specialist networks support revenue depth in developed markets, while private-clinic expansion and local manufacturing are creating faster adoption pathways across emerging regions.
Dermatology Excimer Laser Market Share & Competitive Landscape
The dermatology excimer laser market share structure is moderately concentrated, with the top five companies collectively accounting for 61% of global revenue in 2025. Competition centers on regulatory access, installed-base support, clinical positioning across multiple indications, and the ability to serve both large institutions and smaller dermatology practices.
STRATA Skin Sciences: STRATA Skin Sciences held 22% market share in 2025. Its competitive position is reinforced by its XTRAC platform, reimbursement advocacy, and regulatory expansion efforts that support commercial reach across specialist dermatology settings.
DEKA M.E.L.A.: DEKA M.E.L.A. held 16% market share in 2025. The company competes through established laser-system expertise and its ability to serve clinical buyers seeking broader technology portfolios and durable service support.
Alma Lasers: Alma Lasers held 10% market share in 2025. Its position reflects the importance of channel access, established relationships with aesthetic and dermatology providers, and portfolio-based selling in outpatient care environments.
Sincoheren, Kernel Medical, GSD, LASEROPTEK, PhotoMedex, Daavlin, Lumenis, and KRUPA MEDI SCAN contribute to a competitive environment in which regional manufacturing, regulatory clearances, service capabilities, and practice-level affordability can materially influence purchasing decisions. For newer or regionally focused participants, the ability to pair device access with training, maintenance, and credible clinical positioning is central to gaining share.
Recent Industry Developments
In May 2025, STRATA Skin Sciences announced that the AMA CPT Editorial Panel had accepted revisions to CPT codes 96920-96922, extending reimbursement eligibility for 308 nm excimer laser treatments to inflammatory and autoimmune skin conditions from January 1, 2027. [3]STRATA Skin Sciences. "STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments." investors.strataskinsciences.com
In July 2024, STRATA Skin Sciences announced approval of its XTRAC Momentum 1.0 device in Japan, with commercialization through JMEC Co., Ltd. [6]STRATA Skin Sciences. "STRATA Skin Sciences Announces Approval of XTRAC Momentum™ 1.0 Device in Japan." investors.strataskinsciences.com
In December 2024, Kernel Medical received FDA 510(k) clearance for its 308 nm Excimer Phototherapy Device for psoriasis and vitiligo. [7]FDA. "510(k) Premarket Notification K242977 - 308nm Excimer Phototherapy Device." accessdata.fda.gov
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →